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ABSTRACT 
 
G protein coupled receptors play important roles in cellular signaling and are 
stimulated by a multitude of extracellular signals. These proteins initiate signal 
transduction cascades that elicit a variety of cellular responses. Once activated, G 
protein coupled receptors activate G proteins which further stimulate target proteins to 
elicit cellular responses such as enzyme activity, translation and ion channels60. In this 
study, we set out to solve the crystal structure of a constitutively active form of the alpha 
subunit of the retinal G protein, transducin. This activated G protein, designated as αT* 
SFD QLRC, elicits the ability to stimulate its effector molecule, PDE, to levels 
comparable to activated native retinal alpha. Crystals of αT* SFD QLRC were grown and 
x-ray diffraction data sets were observed at low resolution. Following insights from a 
recent paper by Hu et al, 2018, a C210S mutant was created to help improve diffraction. 
Data sets of αT* SFD QLRC C210S were collected to 2.8 Å and compared to previously 
solved GDP-bound (1TAG) and GTPγS-bound (1TND) native αT subunits. The crystal 
structure of αT* SFD QLRC C210S reveals that despite being fully active in vitro, GDP, 
and not GTP, is bound in the structure. As a result, Switch II and Switch III appear to be 
in a transition state between the inactive GDP-bound state and the active GTP-bound 
state and are un-modelled due to low electron density. Future work involves improving 
crystallization of αT* SFD QLRC C210S to obtain a GTP-bound structure so that the 
structure can be used to elucidate the mechanism by which the transducin α subunit, 
especially the phenylalanine residue of the SFD mutation, confers maximum PDE 
activity.  
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INTRODUCTION 
  
 Vertebrates have developed specialized organs known as the eye to maximize 
light stimulation1,2. The eye consists of a membranous lens which captures light from 
the environment and focuses this light at the back of the eye. Nerve cells at the back of 
the eye known as the retina absorb this light and pass information to the optic nerve and 
brain. To do this, the retina contains specialized nerve cells known as rods and cones. 
Rods and cones absorb light and transmit a chemical signal to the brain which we 
perceive as an image3. What are the underlying biochemical processes that allows us to 
see the world in front of us? After all, light is simply a photon striking our eyes. 
 
The prototypical signaling cascade of G protein-coupled receptors (GPCRs) 
involves a transmembrane receptor, a guanosine nucleotide-binding (G) protein and an 
effector molecule. The transmembrane receptor surveys the extracellular environment 
for signals. Once a stimulant binds to the receptor, structural changes within the 
receptor activates the G protein. Once activated, the G protein will undergo structural 
changes and stimulate effector molecules which change the intracellular concentrations 
of secondary metabolites or other important signaling molecules. This cascade of 
events causes transcriptional, translational or other changes within the cell in response 
to the stimuli. There are various GPCRs, G proteins and effector molecules in the cell 
but all follow the similar pathway shown below (Figure 1). In the vision system, the 
GPCR is rhodopsin, the G protein is transducin and the effector protein is cGMP 
phosphodiesterase (PDE). The visual phototransduction system is a prototypical GPCR 
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signaling cascade.  In this study, we focus on this pathway and the key proteins 
involved.  
 
 
 
Figure 1: The canonical GPCR Signaling pathway within cells.  
  
Rhodopsin is a member of the superfamily of GPCRs. GPCRs constitute the 
largest family of transmembrane proteins in metazoan biology consisting of about 800 
members4 and are targeted by over 30% of all drugs5 on the market. All GPCRs share 
the characteristic seven transmembrane helices and transmit extracellular signals from 
a wide array of signals including; hormones, neurotransmitters, odorants and photons6. 
GPCRs transmit these signals across the plasma membrane and allow cells to survey 
the surrounding environment and respond accordingly.  
 
In humans, each retina contains nearly 109 rod cells which are more sensitive to 
light but cannot distinguish color and 3x106 cone cells which are less sensitive to light 
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but can distinguish color7. This explains why it is difficult to see color in dim light. Rod 
and cone nerve cells each contain the light-sensitive receptor protein, rhodopsin. Native 
rhodopsin has been purified from bovine eye and used in experimentation to better 
understand GPCR and G protein signaling. To learn more about GPCR signaling, 
crystal structures must be obtained to help identify important G protein binding sites. 
Eventually, the three dimensional crystal structure of detergent-solubilized bovine 
rhodopsin was first reported at 2.8 Å resolution8 and recently improved to 2.2 Å9. These 
inactive structures show that rhodopsin folds into a seven transmembrane helix which is 
characteristic among GPCRs.  
 
Rhodopsin is comprised of the ~40kDa protein component, opsin, bound to the 
chromophore moiety, 11-cis-retinal. 11-cis-retinal is bound to opsin10, 55 via a Schiff base 
linkage to the ε-amine of lysine 296 in the middle of transmembrane helix 710. This 
covalently bound inverse agonist, 11-cis retinal, photoisomerizes into all-trans retinal 
which becomes an agonist for rhodopsin upon light-activation11, 57 . The photo-induced 
change in the structure of rhodopsin results in the creation of a binding site along the 
cytosolic helix for the G protein, transducin4. Closely related GPCR and G protein 
complexes have been crystallized and their structures determined.12, 13, 14, 15. 
Additionally, cryo-electron microscopy has been recently used in the lab by Dr. Gao to 
solve the structure of the rhodopsin-transducin complex61. These structures depict the 
binding interactions between the GPCR and G protein. The vertebrate vision system 
was the first GPCR signaling pathway in which each component has been purified and 
crystallized and provides a good example to study a multi-component, GPCR-G protein-
coupled signaling system16. 
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In the active structure, the transmembrane helices of rhodopsin move which 
ultimately result in key changes within the cytosolic region of the receptor17,18. Once 11-
cis retinal absorbs a photon and changes conformation to all-trans-retinal it causes 
structural changes generating the active receptor form known as metarhodopsin II19. 
Metarhodopsin II activates transducin via contacts of the cytosolic helix of the receptor 
and Domain III, the carboxy terminus, of the α subunit of transducin20. Once activated 
by light, metarhodopsin II binds and catalyzes the exchange of GDP for GTP within the 
α subunit of the heterotrimeric G protein, transducin21.  
 
The next step in GPCR signal transduction is G protein activation. In the 
phototransduction cascade, the G protein is transducin. There are two families of G 
proteins, the Ras-related single chain (small) G proteins and the heterotrimeric (large) G 
proteins. Here, we will focus on heterotrimeric G proteins, of which transducin is a 
member. G proteins interact with various effectors within the cell which have diverse 
cellular consequences regulating enzymes, ion channels, transporter proteins and other 
parts of the cell machinery controlling motility, transcription, secretion and contractility60. 
G proteins function as molecular switches, therefore their signaling regulation is 
important to prevent excessive signaling which can be detrimental to an organism’s 
health. In the canonical pathway, GPCRs activate G proteins through GTP/GDP 
exchange while regulator of G protein signaling (RGS) proteins help inactivate G 
proteins by promoting GTP hydrolysis by the α subunit of G-proteins22. The activity of G 
proteins depends on whether GDP or GTP is bound within the α subunit. G proteins are 
activated upon GTP binding and inactivated once GTP is hydrolyzed to GDP58. There 
are various α subunits which activate or inhibit effectors. 
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In contrast to the great diversity of GPCRs (800 members), there are only 16 
genes encoding 21 different α subunits in humans23. This implies that each G protein 
isoform must interact with several different GPCRs. Notably, there is evidence 
supporting that GPCRs, such as the ß2 adrenergic receptor, can couple to more than 
one G protein24. Therefore, proper regulation regarding the specificity between GPCRs 
and G proteins is imperative for normal signal transduction within cells25. Improper 
signaling causes aberrant intracellular responses which can cause the onset of 
diseases at the organismal level such as cancer26, 53. Therefore, it is important to fully 
understand these signaling pathways and to develop new treatments and medicines 
when these pathways are disrupted.  
 
In their inactive basal state G proteins are bound to GDP, however following 
activation of the GPCR via a hormone or other type of signal, GDP dissociates and is 
replaced by cellular GTP. In humans, the intracellular concentration of GTP is about 
ten-fold higher than GDP, therefore GTP is more likely to be exchanged than GDP27. 
The binding of GTP causes a conformational change within the G protein which then 
primes it to interact with the next protein in the signaling pathway such as its target or 
effector protein. GTP hydrolysis by the G protein then returns it to its inactive GDP-
bound state. A summary of this process is shown below (Figure 2).  
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Figure 2: G proteins as molecular switches. Figure depicting the regulatory cycle of 
heterotrimeric G protein subunits28. 
 
 
To send intracellular signals, GPCRs activate their canonical signaling partners, 
large heterotrimeric G proteins. Large heterotrimeric G proteins are comprised of α, ß 
and γ subunits which are ~40-45 kDa, ~35-36 kDa and ~5-10 kDa respectively29. Small, 
Ras-like G proteins are a single chain which is ~21 kDa. Gα subunits contain two 
domains, a domain involved in binding and hydrolyzing GTP (sometimes referred to as 
the G domain or the Ras-like GTPase domain) and a unique helical domain that buries 
GDP or GTP within the core of the protein. The guanine nucleotide-binding, or G, 
domain is highly conserved in G proteins. The ß subunits of large G proteins have a 
seven-membered ß-propeller structure as indicated by the presence of seven WD40 
(tryptophan-aspartic acid) repeats. ß and γ subunits form a functional unit that is not 
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dissociable except by denaturation and function as regulators of the α subunit. ß and γ 
subunits can also function as separate signaling proteins and activate other second 
messengers or by gating ion channels directly30, 31. There are four different types of 
heterotrimeric G proteins based on the amino acid sequence similarity of the α subunits: 
Gs, Gi, Gq, and G12 and each vary in activity with effectors32, 41, 42, 43.. 
 
The first three dimensional structure of a G protein-α subunit solved was of 
transducin. It was solved in an activated conformation (GTPγS-bound) by Sigler and his 
colleagues, and was considered to represent a remarkable breakthrough at the time33. 
This original X-ray crystal structure showed that bound GTPγS, a non-hydrolysable GTP 
analog, molecule was occluded in a deep cleft between a domain structurally 
homologous to Ras and a helical domain unique to heterotrimeric G proteins. The Ras-
like and the helical domain of G protein-α subunits in effect form a “clam shell” that 
seals the bound GTP. This has significant consequences for the mechanism by which 
GPCRs stimulate GDP-GTP exchange and catalyze G protein activation. 
Metarhodopsin II must pry open the “clam shell” to allow GDP to dissociate and allow 
GTP to associate before closing tightly. A number of structures rapidly followed for 
GDP-αT34, GDP35 and GTPγS33-bound αi1, and the αT-ßγ (holo-transducin)34 and αi1-ßγ 
(holo-Gi1)29 complexes. When the structure for the GDP-bound αT subunit was solved, it 
was possible to overlay and compare the structures for an activated and an inactive a 
subunit. This provided key insights into the molecular consequences and structural 
changes of G protein activation that accompanies GTP/GDP exchange.  
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Stimulated rhodopsin induces structural changes within transducin which 
catalyzes GTP/GDP exchange56. Structural changes within the α subunit induced by 
GTP/GDP exchange are localized to three adjacent regions on one face of the protein. 
These regions are referred to as Switch I, II and III due to their essential movement in 
activation. Switch I (Ser173-Thr183) and Switch II (Phe195-Thr215) have counterparts 
in Ras. However, Switch III (Asp227- Arg238) is unique to heterotrimeric G proteins. 
The major helical domain on αT is largely unchanged by GTP/GDP exchange as is the 
α4-ß5 region. The GTP-bound α subunit of transducin, αT, dissociates from the ß and γ 
subunits and can then interact with and activate its effector molecule, PDE, which 
hydrolyzes cGMP to GMP and with the release of a proton. 
 
The crystal structure for holo-transducin was solved and showed two non-
overlapping regions of contact between the α and ß subunits, an extended interface 
between ß and nearly all of γ, and a limited interaction between the α and γ subunits34. 
A major binding interaction between the Gα and Gß subunits involves the Switch II 
domain of the α subunit, with the GTP-bound structural rearrangement of Switch II being 
responsible for the dissociation of the Gα subunit from the Gßγ complex allowing Gα to 
activate PDE36, 37. A second major contact between the Gα and Gß subunits occurs 
within the amino terminal domain of α. WD40 repeats that are found in the Gß subunit 
show up in a variety of other proteins involved in signaling, RNA processing, gene 
regulation, vesicle fusion, and cytoskeletal assembly. These WD40 repeats form a 
circularized seven-fold ß propeller. The N-terminus of Gß adopts an α-helical 
conformation that forms a coiled-coil motif with the N-terminus of Gγ. The C-terminus of 
Gγ binds to blades five and six of the seven-bladed ß-propeller structure. The primary 
9 
 
interaction surface between the Gα and Gß subunits is formed by Switch I and Switch II 
on Gα(GDP) and five of the seven blades of Gß. A smaller interaction is formed between 
the N-terminus of Gα and blade one of Gß. Upon formation of the heterotrimer, Gßγ 
significantly alters the conformation of Switch I and Switch II, which dismantles the 
binding sites for Mg2+ and the γ-phosphate of GTP, consistent with the notion that GTP 
and Gßγ binding to Gα are negatively cooperative. 
 
 The final step of the GPCR signaling cascade is effector activation (PDE6 in the 
visual system). Regulation of this signaling cascade has serious implications in 
diseases such as cancer. In the visual transduction signaling pathways, activated GTP-
bound transducin relieves the inhibitory γ subunit of PDE6 to activate it (the precise 
mechanism is not yet known). Once activated, PDE catalyzes the hydrolysis of cGMP to 
GMP. In neuronal cells, cGMP binds to and opens sodium ion channels in 
photoreceptors allowing sodium cations to freely diffuse into the cell from the 
extracellular environment. However, once cGMP is converted to GMP, the sodium ion 
channels close which prevent cations such as Na+ and Ca2+ from entering the cell. 
Simultaneously, Na+ is transported out of the neuronal cell by another ion channel, 
Na+K+ ATPase38. The result is Na+ being net exported from the cell which will 
hyperpolarize the cell and generate an electrical action potential which transmits the 
stimulus of light to the brain. This is the final step of the vision signal transduction 
cascade54. 
 
 The rhodopsin phototransduction signaling pathway is the paradigm for GPCR 
and G protein signaling. The system offers certain advantages when compared to other 
10 
 
GPCR signaling pathway for obtaining structural insights into GPCR-signaling. Most 
importantly, each of the principal components of the pathway can be purified from native 
tissue in large quantities. As a result, rhodopsin was the first and only GPCR to date for 
which X-ray crystal structures have been solved in native form. While this serves as a 
great advantage over other GPCR signaling pathways, there is one major drawback. To 
better understand critical residues which are paramount for protein-protein interactions 
and function, point mutations must be introduced into the protein. In doing so, critical 
residues for ligand binding, activity, protein-protein interaction, specificity, and 
regulation, can then be elucidated despite large quantities of phototransduction proteins 
readily purified from bovine eye, these proteins are native and cannot be mutated. 
Therefore, it would be highly desirable to reconstitute and express phototransduction 
proteins within a bacterial model because bacteria can be genetically manipulated. 
 
 Each of the primary components of the rhodopsin/transducin-coupled signaling 
pathway has been purified, biochemically characterized, and their interactions 
reconstituted in vitro. This system is ideal for elucidating the underlying mechanisms 
that link the GTP-dependent interactions between a Gα subunit and its biological 
effector. However, to study key sites on Gα subunits for effector regulation, targeted 
mutagenesis followed by bacterial expression must be utilized. αT has previously been 
unsuccessfully expressed in Escherichia coli and thus could not be mutated for further 
studies until a paper published by Skiba et al. In this paper, the researchers spliced 
together two DNA sequences from αT and Gαi1, forming various chimera proteins, one 
variant was designated αT Chi8. This chimera could be expressed in bacteria39. αT Chi8 
is composed of two fragments of αT, residues 216–227 and 237–294, which were 
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replaced with the corresponding residues from another G protein, αil. The E. coli– 
expressed αT Chi8 chimera has greatly facilitated biochemical and crystallographic 
structural studies and expanded the study of G proteins. Despite these great advances, 
αT Chi8, could not stimulate its effector, PDE, to any degree. Further investigation 
revealed that restoration of two residues in the α3 helix of αT (His-244 and Asn-247: HN 
mutant) yielded partial restored PDE activation; αT Chi8 HN. A recent study by Milano et 
al. was able to fully reconstitute PDE effector activity through αT Chi8 HN after further 
mutagenesis. This was achieved through mutating three residues of αT Chi8 HN which 
restored the αG/α4 loop from αT40. This fully active chimera, αT Chi8 HN SFD (from here 
referred to as αT* SFD), could fully stimulate PDE, after GTP/GDP exchange, to levels 
comparable to native transducin from bovine eye. Importantly, further analysis identified 
the critical Phe-283 residue that is essential for conferring maximum stimulatory 
capability upon the retinal Gα subunit. This study aims to highlight the importance of 
these key residues of Gα sites in mediating effector regulation.  
 
Here, we show that further mutagenesis of αT* SFD to αT Chi8 HN SFD QLRC 
(from here referred to as αT* SFD QLRC) formed a constitutively active αT subunit 
without the need for GTP/GDP exchange. The QLRC mutations (Q200L and R174C) 
removed critical residues for GTP hydrolysis within αT and reduced the intrinsic GTP 
hydrolytic activity. This study aims to crystallize αT* SFD QLRC to observe the active 
conformation and gain structural insight of how this αT subunit recovers full PDE activity. 
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MATERIALS AND METHODS 
 
Site-directed Mutagenesis 
 
Sense and antisense oligonucleotide primers were synthesized with the 
sequence including the desired mutated base in the center of the primer. The 
QuikChange site-directed mutagenesis kit (Stratagene) was used for PCR-based 
mutagenesis on miniprep plasmid DNA. The parental DNA template was digested using 
DpnI endonuclease and the nicked vector DNA with the desired mutation was 
transformed into NEB 5-alpha supercompetent cells. A chimeric αT construct, referred to 
as αT Chi8, was obtained from Dr. Heidi Hamm’s laboratory at Vanderbilt University. 
This chimera was generated by substituting two regions of αi1 (residues 216–227 and 
237–294) for the corresponding residues of native retinal αT to facilitate its expression in 
E. coli. A modified chimera was created by mutating residues K244H and D247N in αT-
Chi8, resulting in a chimeric G subunit referred to as HN. Further mutation of residues 
yielded the αT Chi8 HN SFD QLRC mutant which was later expressed in BL21 (DE3) 
supercompetent cells, purified and crystallized. 
 
Expression and purification of αT*SFD QLRC 
 
BL21 cells were transformed by incubating 1µg of DNA with bacteria on ice for 15 
minutes. The bacteria were then heat shocked at 45oC for 30 seconds before being 
placed immediately back on ice. Transformed bacteria were grown for 1 hour in a 37oC 
shaker incubator in SOC growth media. Transformed bacteria were placed on lysogeny 
broth (LB)-Agar-ampicillin plates to select for colonies overnight. Single colonies were 
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picked after an overnight incubation at 37oC and bacteria were cultured overnight in a 
125 mL starter culture containing LB with 100 mg/L ampicillin at 37oC on a shaker. 
Bacteria were then cultured in 1L flasks containing autoclaved media consisting of 12 
g/L tryptone, 24 g/L yeast extract, 4 mL pure glycine, 2.3 g/L KH2PO4, 12.5 g/L K2HPO4 
and 100 mg/L ampicillin. Cultures were grown for 3-6 hours in a 37oC table shaker until 
an optical density of 0.6 - 0.8 was reached. 30 µM IPTG was added to induce plasmid 
expression overnight at 23oC on a table shaker. Cultures were then centrifuged for 10 
minutes at 5000 rpm at 4oC using a JLA 10.500 rotor (Beckman Coulter) and an Avanti 
J-25I centrifuge (Beckman Coulter). Bacteria pellets were collected and stored at -20oC 
until further use. Bacteria were lysed using lysis buffer consisting of 50mM Tris, 50mM 
NaCl, 5mM MgCl2, 5 mM ß-mercaptoethanol, 1mM GDP, and 0.1 mM PMSF using an 
ultrasonic converter connected to a 550 sonic dismembrator (Fisher Scientific) sonicator 
on ice. Bacteria lysates were centrifuged for 45 minutes at 40,000 g at 4oC under 
vacuum using a TI45 rotor and Optima LE-80K ultracentrifuge Beckman Coulter 
ultracentrifuge. Bacterial lysis supernatant was passed over a sepharose column 
charged with 250 mM NiSO4. Supernatant was incubated with the charged nickel 
column for 5 minutes at 4oC before starting elution. Stepwise elution followed with three 
buffers and fractions were collected once the third buffer was added. Nickel column 
buffer 1 consisted of 50 mM Tris pH 8.0, 500 mM NaCl, 20 mM imidazole, 50 µM GDP 
and 5 mM ß-mercaptoethanol. Nickel column buffer 2 consisted of 50 mM Tris pH 8.0, 
20 mM imidazole, 50 µM GDP and 5 mM ß-mercaptoethanol. Nickel affinity column 
buffer 3 consisted of 50 mM Tris pH 8.0, 500 mM NaCl, 100 mM imidazole, 50 µM GDP 
and 5 mM ß-mercaptoethanol. The proteins were further purified by ion exchange 
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chromatography using a HiTrap Q FF Sepharose column (GE Healthcare Life Sciences) 
using a buffer containing 50 mM Tris pH 8.0, 5 mM MgCl2, 1 mM DTT, 10% glycerol, 25 
µM GDP and a linear concentration gradient of NaCl from 20 mM to 1 M. 5 mL fractions 
were collected until 15 fractions were collected and then 2 mL fractions were collected 
to improve elution resolution. The chromatography peaks containing αT Chi8 HN SFD 
QLRC were pooled and passed through a HiLoad Superdex 75 gel filtration column (GE 
Healthcare) size exclusion chromatography column using a buffer containing 20 mM 
Na-HEPES pH 7.5, 5 mM MgCl2, 100 mM NaCl, 10% glycerol and 1 mM DTT. All 
purification buffers were filtered using a nylon membrane 0.20 µm GNWP filter (Merck 
Millipore Ltd.). Fractions containing αT Chi8 HN SFD QLRC were pooled and 
concentrated if necessary to 10 mg/mL using Ultracel 10K centrifugal filters (Amicon) 
and snap frozen and stored at -80oC. Protein concentrations were determined by using 
absorbance at 280 nm and the calculated molar extinction coefficient. The molar 
extinction coefficient was calculated from their sequence using the ExPASy ProtParam 
tool (https://web.expasy.org/protparam/). To verify protein purity, samples were run on a 
Novex WedgeWell 4-20% Tris-glycine gel (Invitrogen) alongside a Precision Plus 
Protein Standard (BioRad). The gel was then stained for all proteins using Coomassie 
Blue fast stain (Gene Copoeia). Rhodopsin was purified as described here16. 
 
Crystallization  
 
 Purified αT* SFD QLRC was concentrated to 10 mg/mL and screened under 
many conditions using the Gryphon (Art Robbins Instruments). Several 96 well screens 
from Hampton Research were used to find conditions that promoted crystallization. 
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Screens included Index, 50% compass, SaltRx, Grid Screen Salt and Crystal screen 
(Hampton Research). Once initial crystal conditions were identified, finer screens in 24 
well plates were set up to optimize crystal growth, size, quality and quantity. Hanging 
drop vapor diffusion was used for crystal growth under conditions consisting of 2.4 M 
(NH4)2SO4 and 0.1 M sodium cacodylate pH 6.0. Crystals were then picked using nylon 
magnetic loops (Hampton Research) and flash frozen in liquid nitrogen with 3.2 M 
(NH4)2SO4 and 0.1 M sodium cacodylate cryoprotectant and stored in liquid nitrogen 
until diffracted at the Cornell High Energy Synchrotron Source (CHESS) at Cornell 
University, Ithaca, NY. Diffraction images were collected on the F2 beamline. All 
components used for crystallization solutions were acquired through Hampton 
Research. 
 
Structure Determination 
 
 At CHESS, diffraction images were collected on the F2 beamline. Diffraction 
images were collected while the crystal diffracted under a cryo stream. HKL2000 (HKL 
Research Inc)44 was used to determine the space group and integrate the images into 
an MTZ file.  Python-Based Hierarchical ENvironment for Integrated Xtallography 
version (PHENIX)45 was used for molecular replacement using the 1TND (GTPγS-
bound) pdb model to solve the structure. PHENIX and coot52 were used to refine the 
three-dimensional structure within the electron density. Several rounds of refinement 
were used to optimize integration in PHENIX. 
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Purification of retinal proteins 
 
The exact procedure was followed from Milano et al40. Bovine rod outer segment 
membranes were isolated using a sucrose gradient as described previously46. Urea-
washed disc membranes were prepared as described and served as the source of light-
activated rhodopsin47. PDE and transducin were isolated by washing rod outer segment 
membranes with hypotonic buffer in the absence and presence of GTP. The αT subunit 
and ß1γ1 subunit complex of transducin were resolved on a HiTrap Blue Sepharose 
column (GE Healthcare). The column was first washed with a buffer containing 10 mM 
NaHEPES, pH 7.5, 6 mM MgCl2,1mM DTT, 100 mM KCl, and 10% glycerol to elute the 
ß1γ1 complex. To elute αT, a buffer containing 10 mM Na-HEPES, pH 7.5, 6 mM MgCl2, 
1mM DTT, 500 mM KCl, and 10% glycerol was subsequently applied onto the column. 
All transducin subunits and holo-PDE were loaded on HiLoad Superdex 75 and 
Superdex 200 gel filtration columns (GE Healthcare), respectively, and eluted with a 
buffer containing 20 mM Na-HEPES, pH 7.4, 5 mM MgCl2, 100 mM NaCl, and 1 mM 
DTT. The pure retinal proteins were concentrated to 20 µM, snap frozen, and stored at 
80°C. 
 
PDE Effector pH Assay 
 
PDE activity was measured through cGMP hydrolysis and determined by the 
change in buffer capacity over time. 200 µL of reaction buffer containing 10 mM Tris pH 
8.0, 2 mM MgCl2 and 100 mM NaCl and GTPγS-loaded αT subunits, at varying 
concentrations, were incubated with either holo-PDE or reconstituted PDE (50 nM) in a 
96 well plate. The pH (in millivolts) was monitored in real time and once a stable 
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baseline was achieved, 5 mM cGMP was added and the decrease in pH was recorded 
for 150 s. The buffer capacity of the mixture was then determined by adding NaOH (400 
nmol). The hydrolysis rate of cGMP (nmol/s) was determined from the ratio of the initial 
slope of the ph record from cGMP hydrolysis (mV/s) and the buffer capacity of the 
assay buffer (mV/nmol). 
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RESULTS 
 
Purification of αT Chimeras 
 
Previous studies have purified αT chimeras from bacterial systems using similar 
methods. The construct of these αT chimeras have a C-terminus 6 repeat histidine tag 
as histidine residues have high affinity for nickel and strongly coordinate with nickel ions 
bound to the stationary phase in the column. Genetically engineering a His-tag into the 
protein constructs allows for separation of αT from the majority of other proteins within 
the E. coli cells via affinity chromatography. Imidazole is used for elution and as its six 
pi-electrons coordinate nickel more strongly than does histidine. As increasing 
concentrations of imidazole are added to the column, first the more weakly associated 
proteins lacking any His-tag elute. Only in the third buffer, and at the highest imidazole 
concentration, is the His-tag protein eluted and collected for further purification.  
 
The next step of purification is ion-exchange chromatography where separation 
is based on the reversible interaction between a charged protein and an oppositely 
charged chromatography resin. Increasing concentrations of NaCl are used to elute 
proteins from the ion-exchange column. Fractions containing the highest αT 
concentration are pooled together and run over the gel-filtration column. This column 
consists of the stationary phase in which the beads have tunnels of pores that run 
through the interior of the bead. Small sized proteins interact with these pores more 
than do larger proteins which cannot fit into these pores and thus larger proteins elute 
faster than small proteins. This is the final step in purification and selects for a ~40kDa 
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protein, αT* SFD QLRC (Figure 3). The coomassie gel was overloaded with 20 µg of 
purified αT to reveal contaminant co-purified proteins. Co-purified proteins are likely to 
associate with αT and evade the series of chromatography columns. The purity of 
protein strongly influences its ability to form highly diffracting crystals. 
 
 
 
 
 
 
 
 
 
Figure 3: Purification of αT* SFD QLRC. Coomassie stained gel of the purified α 
subunit of transducin. Precision Plus Protein Standard (BioRad) was loaded into lane 1 
and served as a marker for protein molecular weight. Lanes 2 through 5 were added 
with 0, 5, 10 and 20 µg of purified αT. The gel was stained with Coomassie Blue fast 
stain (Gene Copoeia) and destained overnight. Proteins retain the coomassie stain and 
are seen as horizontal blue bands. The dark blue band at ~40 kDa represents purified 
αT* SFD QLRC. 
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αT* SFD QLRC effector activity 
 
The immediate biological effector of αT is PDE. The first step after purifying αT 
was to access its ability to activate PDE. Once rhodopsin catalyzes the exchange of 
GDP for GTP within the GTPase domain of αT, the ß and γ subunits dissociate. αT 
dissociates from rhodopsin and binds to and activates PDE by relieving the inhibitory γ 
subunit47. Once activated, PDE hydrolyzes the cyclic phosphodiester bond bound to the 
3’ hydroxyl group of deoxyribose of guanosine. 5’-GMP and a proton are generated as 
products. Therefore, by monitoring the change in pH as a function of buffer capacity, the 
ability of αT to activate PDE can be measured. Previous experiments, by Milano et al 
2018, showed that the SFD mutant was GDP-bound and must be exchanged with GTP 
using rhodopsin, ß and γ subunits of transducin as well as light. In doing so, the activity 
of SFD increased to levels comparable to retinal α. Without GTP exchange, SFD 
showed minimal activity, similar to GDP-bound retinal α. These data show that the SFD 
mutant is normally bound to GDP and must be exchanged to GTP to become active. 
However, the αT* SFD QLRC mutant showed maximal activity without rhodopsin-
catalyzed exchange. These results suggest that αT* SFD QLRC either is bound to GTP 
or constitutively in an active conformation and able to activate PDE (Figure 2). HPLC 
data using elution absorbance peaks of GDP and GTP reveal that αT* SFD QLRC 
elutes mainly with GTP and a minor population with GDP (data not shown). This 
suggests that αT* SFD QLRC binds to GTP in favor of GDP. Site-directed mutagenesis 
was performed to create the αT* SFD QLRC mutations which have been shown 
previously to reduce GTP hydrolysis within the GTPase domain of α subunits48. 
Therefore, once αT* SFD QLRC binds to GTP, it will be in an active conformation. Our 
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results are consistent with these previous findings. However, to prove this, the crystal 
structure of αT* SFD QLRC must be solved.  
Figure 4: αT* SFD QLRC effector activity. PDE stimulation by αT subunits. The activity 
of PDE as monitored by pH and graphed as the relative rate of cGMP hydrolysis. 
Retinal α from bovine eye were purified, αT SFD and αT SFD QLRC from E. coli were 
purified and were assayed for activity. Only retinal alpha and SFD were exchanged with 
GTP using activated rhodopsin. The concentration of the αT subunits used in this 
experiment was 1µM. The percent rates of cGMP hydrolysis of the αT subunits were 
plotted relative to the levels of cGMP hydrolysis stimulated by native retinal αT. Data is 
represented as a mean with ± S.E.(error bars) of at least three replicates. 
 
Structure Determination of αT* SFD QLRC C210S 
 
 
 Initially, αT* SFD QLRC crystal trays were set up. Crystals formed but diffracted 
weakly. However, a recently published paper revealed that creating cysteine mutations 
within an αs subunit of a G protein helps promote crystallization in the active 
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conformation4. To help improve crystal diffraction, a similar mutant of αT was made. The 
final protein construct is now noted as αT* SFD QLRC C210S. 
 
αT* SFD QLRC C210S crystals were grown (as shown below in Figure 5A) and 
diffracted to 2.8 Å. Diffraction images from CHESS are shown (Figure 5B) and a 
summary of crystal statistics is tabled (Figure 5C). The crystal structure was solved to 
2.8 Å and is shown below (Figure 5D and E). The overall structure is shown in gray and 
the three Switch regions are colored. Switch I is colored in red, Switch II in blue and 
Switch III in purple. The helical domain, GTPase domain, effector binding domain and 
receptor binding domain are shown. The structure contains GDP as shown in green. 
The model is shown in cartoon format to reveal secondary structures except for switch 
regions shown as sticks for clarity.  
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Figure 5: Diffraction and structure of αT* SFD QLRC C210S crystals: Crystallized 
αT* SFD QLRC C210S diffracted to 2.8 Å. A. crystals seen under the microscope in the 
hanging drop vapor diffusion tray. B. diffraction image of the crystals at CHESS. C. 
summary of crystallographic diffraction statistics and refinement. Diffraction images 
were indexed and integrated using HKL2000. Phenix and coot were used for 3d 
modelling and refinement. D and E. the 3d crystal structure solved to 2.8 Å. The overall 
structure (gray) with GDP bound (green) and the three Switch regions, I (red), II (blue) 
and III (purple). The structure is shown in cartoon style to highlight secondary structures 
while GDP and the Switch regions are shown in stick style. The important regions of αT 
are depicted as extended brackets and labels. The protein is viewed from two angles: 0 
degrees (D) and 90 degrees (E). Images were created using PyMOL. 
 
 
Comparison of αT* SFD QLRC C210S to native αT GDP and GTPγS structures 
 
Interestingly, the mutant protein shows full ability to activate its effector, PDE, but 
is somehow bound to GDP instead of GTP. Therefore, the crystal structure was aligned 
with other retinal αT crystal structures either bound to GDP or GTPγS (Figure 6). The 
αT* SFD QLRC C210S structure (green) was aligned with both the GDP-bound 
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structure, 1TAG (purple) and the GTPγS-bound structure, 1TND (yellow). Images were 
created using the same alignments and field of view in PyMOL49. Overall, the global 
structures of the three proteins are highly similar. Because the αT* SFD QLRC C201S 
structure showed density for GDP, we compared the guanosine-binding pocket of αT* 
SFD QLRC C201S to both GDP-bound and GTPγS-bound structures. The aligned 
structures show strong similarity in the binding pocket to one another. The only notable 
difference seen is in the GTPγS-bound structure where GLY-199 moves to form a 
hydrogen bond with the γ-phosphate of GTPγS so as to accommodate the additional 
phosphate. Also, in the GTPγS-bound structure there is a Mg2+ cation that coordinates 
with oxygen atoms from both the ß and γ-phosphate of GTPγS (not shown). 
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Figure 6: Crystal structure of αT* SFD QLRC C210S overlapped with 1TND and 
1TND. The crystal structure of αT* SFD QLRC C210S (green) was aligned with the 
GDP-bound 1TAG structure (purple) and also the 1TND GTPγS 1TND structure 
(yellow). A, B show the overall structure of αT* SFD QLRC C210S aligned to either 
1TAG or 1TND, respectively. The view was rotated 90 degrees to help visualize of the 
structure. C, D alignment of αT* SFD QLRC C210S to either 1TAG or 1TND viewing the 
guanosine nucleotide binding pocket. Residues and their sequence numbers have been 
labelled. Note that residue 174 has been mutated from arginine to cysteine in the αT* 
SFD QLRC C210S structure and is not labeled. An extra phosphate group can be seen 
in D which is the γ phosphate of GTPγS. E, F alignment viewing the Switch I region. G, 
H alignment viewing the Switch II region. I, J alignment viewing the Switch III region. 
Switch II and III for αT* SFD QLRC C210S (green) have unmodelled regions due to 
weak electron density and have missing residues. Each end of the Switch regions are 
labelled to help identify polarity. 
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DISCUSSION 
 
This work is important because we can use this active αT subunit to study its 
interactions with PDE. By understanding how transducin activates PDE, not only will we 
better understand the phototransduction signaling pathway but also the other closely 
related GPCR pathways. GPCRs and their associated proteins in signal transduction 
present a vast opportunity to develop medicines to treat diseases where these signaling 
pathways become disrupted. This study aims to further our understanding of G proteins 
so that we can develop treatments for when aberrant signaling arises as seen in 
cancer26.  
 
In this work we crystallized an active form of αT to see how this chimera activates 
its effector, PDE. We solved structures of a chimeric αT subunit mutated to αT* SFD and 
then a constitutively active form, αT* SFD QLRC, which were expressed in E. coli. To 
understand more about G protein signaling, we first used site directed mutagenesis to 
identify critical residues for GTP hydrolysis. Previous studies by Hargrave et al. 
identified that αT Chi8 can be expressed in a bacterial system and provided a starting 
point for further studies. However, αT Chi8 could not activate its effector protein, PDE. 
Further mutagenesis by Majumdar et al. showed αT Chi8 HN was able to restore partial 
effector activity51. To restore full effector activity, Milano et al 2018, showed that a 
critical phenylalanine residue within αT Chi8 HN SFD (αT* SFD) was necessary to fully 
restore effector activity. We have extended the story by creating a new αT mutant which 
is constitutively active and stimulates PDE despite the absence of rhodopsin. 
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Generation of this mutant can help us better understand the mechanism by which G 
proteins activate effector proteins.  
 
Originally, we grew crystals of αT* SFD in hopes of determining the crystal 
structure of the active conformation. In doing so, we could compare the chimeric 
structure to retinal transducin to learn how the critical phenylalanine residue confers 
maximum PDE activation. However, these crystals diffracted weakly (>3.0 Å) and 
yielded the inactive GDP-bound state. In crystallography, it is important to obtain the 
highest resolution structure because higher resolution structures have more resolved 
electron density. As an example, aromatic structures of low resolution structures look 
like flat discs. However, in high resolution structures, the electron density is much more 
refined and now resembles a flat disc with a circular hole in the center. Higher resolution 
structures better resemble the true three dimensional shape of the protein and greatly 
facilitate modelling. In higher resolution structures, the electron density reveals specific 
atomic interactions. For example, higher resolution structures of G proteins can reveal 
the atoms within the protein that interact with atoms of guanosine. On the contrary, 
lower resolution structures have less refined electron density and may only show the 
residues which interact with guanosine and not the individual atoms involved. The 
ultimate resolution is limited by the wavelength of the X-ray beam used. An X-ray beam 
is on the same order of length as atomic bonds and interacts with the electrons which 
form these bonds. Therefore, the maximum resolution using this technique is ~1.0 Å.  
 
 To help create an active state crystal structure, the αT* SFD QLRC mutant was 
made. It is well known that the Q200L mutation replaces the binding of a glutamate 
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residue, which normally binds to the γ phosphate of GTP, to a rather inert leucine which 
helps reduce the GTPase activity. The R174C mutation replaces the arginine finger 
residue which is analogous to arginine fingers found in GTPase-accelerating proteins 
(GAPs). Normally, GAPs bind to GTP within activated Gα subunits using an arginine 
finger and stimulate the G protein’s intrinsic GTP hydrolytic activity. By mutating 
arginine to cysteine, the GTPase activity of αT was reduced. The αT* SFD QLRC protein 
was fully able to stimulate PDE without the need for GTP/GDP exchange (Figure 4). 
These mutations created a constitutively active form of αT of which we hoped to solve 
the crystal structure. Despite these hopes, the crystal structure revealed GDP instead of 
GTP was bound.  
 
In a further effort to crystallize the αT* SFD QLRC mutant bound to GTP, 
inspiration from literature has provided some insight51. A recent paper by Hu et. al 2018, 
crystallizes a GαS subunit to 1.7 Å. In that study the researchers mutate residue 201 
from arginine to cysteine. The researchers claim that this mutation decreases the GTP 
hydrolysis rate and may change the protein conformation to affect Mg2+ and nucleotide 
properties and promote crystallization of the GTP-bound state (similar to our R174C). 
The researchers explain a second mutation of residue 237, from serine to cysteine, was 
necessary to crystallize GαS and improve diffraction to 1.7 Å. To identify the 
corresponding residues within αT, the GαS sequence was aligned with αT and the 
corresponding residue of αT was mutated to match the mutation in GαS. One of the two 
mutations, R1741C, was already present in the αT* SFD QLRC construct. Using the 
sequence alignment, the second residue in αT* SFD QLRC, 210, was mutated from 
serine to cysteine. The resulting αT* SFD QLRC C210S mutant was created in hopes of 
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obtaining a GTP-bound structure. This mutant protein was expressed, purified, and 
crystallized.  
 
 Crystals diffracted to about 2.8 Å but interestingly still contained GDP in the 
crystal structure. This result is intriguing because αT was crystallized using GTPγS, a 
GTP analog that is hydrolyzed very slowly. Perhaps when the mutant protein is 
expressed in E. coli a fraction of purified mutant protein is bound to GDP. Perhaps the 
crystallization conditions select for the minor GDP-bound state while the GTPγS-bound 
state remains in solution or precipitates as seen in Figure 5A. Concerning the structure 
of the GDP-bound state, the αT* SFD QLRC C210S mutant shows similarities in global 
alignment and guanosine binding to both the GDP-bound and GTP-bound structures 
(Figure 6).  
 
Next, we compared the switch regions of αT* SFD QLRC C210S to each native 
structure. Switch I had high electron density and was modelled well unlike Switch II and 
III. The structure of Switch I looks similar to both GDP and GTPγS crystals and cannot 
be characterized as either in active or inactive conformation. Low electron density of 
both Switch II and III made it difficult to determine which conformation the αT* SFD 
QLRC C210S mutant more closely resembles. Due to the low electron density, the 
structure cannot be modeled in these regions. Amino acids excluded from Switch II 
include: 201-206. Amino acids excluded from Switch III include: 229-235. However, as 
evident by the weak electron density in Switch II and III, the mutant appears to be in a 
transition state between GDP and GTP bound states. Perhaps the protein transitions 
between active and inactive states and therefore results in flexible regions (Figure 4). It 
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is known that the Switch regions move when transducin binds GTP and may explain 
these results. Normally, the Switch regions are structured in retinal α when bound to 
GDP or GTP as seen in Figure 6. Therefore, GDP may not be insufficient to stabilize the 
active conformation. Further work is needed to obtain crystals which diffract well and 
have structured Switch II and III regions.  
 
Before the αT chimera was developed for expression in E. coli, only retinal 
structures existed. In these structures, and other Gα proteins, the first 25 residues were 
cleaved to promote crystallization and diffraction. Cleaving these C-terminal residues 
removes lipid-anchoring hydrophobic residues. Additionally, these residues are modified 
with a 14-carbon saturated fatty acid chain (myristoylation) which also tethers the α 
subunit to the membrane and rhodopsin. By removing these residues, αT becomes 
more soluble and promotes crystallization. In the αT* SFD QLRC C210S structure, the 
first 25 residues have not been cleaved (Figure 5) while both the GDP and GTP bound 
structures have been cleaved. (Figures 6A and 6B). Recent experiments aim to remove 
the first 25 residues to improve diffraction. Using polymerase chain reaction, (PCR), a 
SUMO or TEV sequence can be inserted between residues 25 and 26 of αT* SFD 
QLRC C210S. These certain protein sequences can be specifically recognized and 
cleaved by their respective proteases. Both SUMO and TEV cleavage techniques are 
currently being implemented to remove the first 25 residues. Since the native structures 
could not be mutated the endoprotease, LysC, was employed to cleave polypeptides on 
the C-terminal side of lysines to remove the first 25 residues of α subunits. As one 
caveat, LysC digestion can be over incubated and degrade protein beyond the desired 
cleavage length. Using SUMO and TEV proteases instead of LysC provides more 
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control and may yield higher diffracting crystals. Crystal screens for αT* SFD QLRC 
C210S SUMO or TEV mutants have been set up and new conditions are being 
searched for. 
 
 Another step to improve the structure is to express these mutant proteins in 
insect cells. Insect cells are eukaryotic and are currently used in the lab to purify other 
proteins such as rhodopsin. Insect cells have the advantage of post-translationally 
modifying proteins unlike prokaryotic bacterial cells. Perhaps expression in insect cells 
may increase protein yields and improve diffraction. If so, the structure may contain 
GTP and have structured Switch II and Switch III regions. In doing so, we can observe 
how the structure of the constitutively active αT* SFD QLRC C210S mutant (the 
phenylalanine residue in particular) activates PDE. By creating this mutant and solving 
its crystal structure, we hope to improve G protein research in vitro.  
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